Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Spinal Neoplasms | 25 | 2024 | 632 | 3.600 |
Why?
|
Bone Neoplasms | 20 | 2024 | 2580 | 3.150 |
Why?
|
Chondrosarcoma | 5 | 2023 | 216 | 2.430 |
Why?
|
Radiosurgery | 22 | 2024 | 1332 | 2.150 |
Why?
|
Soft Tissue Neoplasms | 8 | 2022 | 883 | 1.870 |
Why?
|
Chordoma | 5 | 2023 | 163 | 1.550 |
Why?
|
Multiple Myeloma | 15 | 2024 | 2150 | 1.370 |
Why?
|
Sarcoma | 10 | 2024 | 1726 | 1.260 |
Why?
|
Chondroma | 2 | 2020 | 31 | 1.250 |
Why?
|
Radiology | 7 | 2022 | 434 | 1.240 |
Why?
|
Magnetic Resonance Imaging | 26 | 2024 | 7727 | 1.220 |
Why?
|
Diagnostic Imaging | 10 | 2020 | 1162 | 1.210 |
Why?
|
Fluorodeoxyglucose F18 | 5 | 2020 | 1238 | 1.090 |
Why?
|
Positron Emission Tomography Computed Tomography | 6 | 2022 | 845 | 1.050 |
Why?
|
Liposarcoma | 4 | 2022 | 214 | 0.980 |
Why?
|
Fibromatosis, Aggressive | 3 | 2022 | 109 | 0.850 |
Why?
|
Ankle | 2 | 2018 | 36 | 0.820 |
Why?
|
Sarcopenia | 2 | 2021 | 110 | 0.800 |
Why?
|
Pseudomyxoma Peritonei | 1 | 2021 | 38 | 0.800 |
Why?
|
Osteosarcoma | 4 | 2022 | 931 | 0.800 |
Why?
|
Internship and Residency | 4 | 2021 | 1410 | 0.790 |
Why?
|
Teaching Materials | 2 | 2018 | 21 | 0.780 |
Why?
|
Spinal Cord Compression | 6 | 2017 | 151 | 0.770 |
Why?
|
Fibrous Dysplasia of Bone | 1 | 2020 | 11 | 0.760 |
Why?
|
Chondroblastoma | 1 | 2020 | 15 | 0.760 |
Why?
|
Osteoblastoma | 1 | 2020 | 15 | 0.750 |
Why?
|
Arthralgia | 4 | 2019 | 96 | 0.750 |
Why?
|
Osteoma, Osteoid | 1 | 2020 | 22 | 0.750 |
Why?
|
Software | 2 | 2018 | 1325 | 0.750 |
Why?
|
Spine | 4 | 2022 | 294 | 0.740 |
Why?
|
Oncologists | 1 | 2022 | 134 | 0.730 |
Why?
|
Bursitis | 2 | 2017 | 10 | 0.730 |
Why?
|
Contrast Media | 8 | 2020 | 1475 | 0.710 |
Why?
|
Radiopharmaceuticals | 6 | 2020 | 1311 | 0.680 |
Why?
|
Humans | 123 | 2024 | 262210 | 0.680 |
Why?
|
Appendiceal Neoplasms | 1 | 2021 | 234 | 0.670 |
Why?
|
Shoulder Joint | 2 | 2017 | 90 | 0.660 |
Why?
|
Multimodal Imaging | 6 | 2020 | 550 | 0.650 |
Why?
|
Diagnosis, Differential | 12 | 2021 | 4756 | 0.650 |
Why?
|
Health Physics | 1 | 2018 | 63 | 0.630 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 2021 | 436 | 0.630 |
Why?
|
Foot | 1 | 2018 | 104 | 0.630 |
Why?
|
Neoplasm Recurrence, Local | 15 | 2024 | 10066 | 0.620 |
Why?
|
Bone Diseases | 2 | 2019 | 143 | 0.570 |
Why?
|
Radiologists | 4 | 2022 | 163 | 0.560 |
Why?
|
Spinal Fractures | 3 | 2024 | 132 | 0.540 |
Why?
|
Paraproteinemias | 1 | 2016 | 61 | 0.540 |
Why?
|
Positron-Emission Tomography | 4 | 2020 | 2184 | 0.530 |
Why?
|
Tomography, X-Ray Computed | 11 | 2024 | 7573 | 0.530 |
Why?
|
Laser Therapy | 5 | 2017 | 411 | 0.520 |
Why?
|
Li-Fraumeni Syndrome | 3 | 2022 | 158 | 0.510 |
Why?
|
Muscle, Skeletal | 4 | 2023 | 1275 | 0.510 |
Why?
|
Models, Neurological | 3 | 2005 | 225 | 0.510 |
Why?
|
Neoplasm Regression, Spontaneous | 1 | 2014 | 34 | 0.510 |
Why?
|
Acetabulum | 1 | 2014 | 38 | 0.500 |
Why?
|
Joint Diseases | 1 | 2014 | 71 | 0.480 |
Why?
|
Respiratory Tract Neoplasms | 1 | 2013 | 37 | 0.450 |
Why?
|
Action Potentials | 3 | 2005 | 562 | 0.450 |
Why?
|
Connective Tissue Diseases | 1 | 2013 | 50 | 0.440 |
Why?
|
Quality Improvement | 1 | 2020 | 855 | 0.430 |
Why?
|
Computed Tomography Angiography | 3 | 2019 | 234 | 0.410 |
Why?
|
Multidetector Computed Tomography | 1 | 2013 | 151 | 0.410 |
Why?
|
Lipoma | 2 | 2023 | 89 | 0.410 |
Why?
|
Retrospective Studies | 29 | 2024 | 38006 | 0.410 |
Why?
|
Middle Aged | 47 | 2024 | 86445 | 0.390 |
Why?
|
Male | 55 | 2023 | 123277 | 0.380 |
Why?
|
Nuclear Medicine | 1 | 2011 | 46 | 0.370 |
Why?
|
Chronic Pain | 3 | 2018 | 247 | 0.360 |
Why?
|
Fractures, Compression | 2 | 2024 | 42 | 0.360 |
Why?
|
Biomedical Research | 1 | 2017 | 807 | 0.360 |
Why?
|
Histiocytosis, Langerhans-Cell | 1 | 2013 | 261 | 0.360 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2013 | 552 | 0.340 |
Why?
|
Plasmacytoma | 2 | 2021 | 111 | 0.340 |
Why?
|
Gadolinium | 2 | 2020 | 165 | 0.330 |
Why?
|
Hyperthermia, Induced | 4 | 2017 | 511 | 0.330 |
Why?
|
Aged | 40 | 2023 | 70322 | 0.320 |
Why?
|
Computer-Assisted Instruction | 2 | 2019 | 81 | 0.320 |
Why?
|
Biological Clocks | 2 | 2005 | 45 | 0.320 |
Why?
|
Thigh | 2 | 2021 | 172 | 0.320 |
Why?
|
Societies, Medical | 9 | 2020 | 1340 | 0.310 |
Why?
|
Chondrosarcoma, Mesenchymal | 2 | 2018 | 17 | 0.310 |
Why?
|
Scapula | 2 | 2019 | 37 | 0.300 |
Why?
|
Lyme Disease | 1 | 2007 | 34 | 0.300 |
Why?
|
Magnetic Resonance Imaging, Interventional | 3 | 2017 | 97 | 0.300 |
Why?
|
Osteoarthritis, Hip | 1 | 2007 | 36 | 0.300 |
Why?
|
Adult | 42 | 2023 | 78087 | 0.290 |
Why?
|
Methylphenidate | 2 | 2004 | 101 | 0.290 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 2 | 2019 | 301 | 0.280 |
Why?
|
Sarcoma, Synovial | 2 | 2017 | 120 | 0.270 |
Why?
|
Female | 46 | 2024 | 142240 | 0.270 |
Why?
|
Central Nervous System Stimulants | 2 | 2004 | 223 | 0.270 |
Why?
|
Fractures, Bone | 2 | 2023 | 291 | 0.260 |
Why?
|
Retroperitoneal Neoplasms | 2 | 2019 | 262 | 0.260 |
Why?
|
Evidence-Based Medicine | 7 | 2020 | 1098 | 0.260 |
Why?
|
Hodgkin Disease | 2 | 2024 | 1431 | 0.250 |
Why?
|
Young Adult | 20 | 2024 | 21474 | 0.250 |
Why?
|
Phrenic Nerve | 1 | 2004 | 16 | 0.250 |
Why?
|
Sensitivity and Specificity | 3 | 2020 | 4977 | 0.240 |
Why?
|
Radiotherapy, Intensity-Modulated | 4 | 2019 | 2107 | 0.240 |
Why?
|
Respiratory Mechanics | 1 | 2005 | 173 | 0.240 |
Why?
|
Radionuclide Imaging | 3 | 2024 | 660 | 0.240 |
Why?
|
Emergency Service, Hospital | 2 | 2015 | 1155 | 0.240 |
Why?
|
Calcinosis | 2 | 2018 | 425 | 0.240 |
Why?
|
Benzophenones | 1 | 2023 | 12 | 0.240 |
Why?
|
Aged, 80 and over | 22 | 2022 | 29997 | 0.240 |
Why?
|
Free Tissue Flaps | 2 | 2019 | 372 | 0.240 |
Why?
|
Pedicle Screws | 1 | 2023 | 10 | 0.230 |
Why?
|
Motor Neurons | 1 | 2004 | 139 | 0.230 |
Why?
|
Sacrum | 2 | 2023 | 134 | 0.220 |
Why?
|
Plastics | 1 | 2023 | 93 | 0.220 |
Why?
|
Prognosis | 16 | 2022 | 21747 | 0.220 |
Why?
|
Neck Injuries | 1 | 2023 | 32 | 0.220 |
Why?
|
Treatment Outcome | 20 | 2023 | 32987 | 0.220 |
Why?
|
Calibration | 2 | 2020 | 337 | 0.210 |
Why?
|
Nerve Net | 1 | 2005 | 257 | 0.210 |
Why?
|
Spinal Fusion | 1 | 2023 | 149 | 0.210 |
Why?
|
Polymers | 1 | 2023 | 225 | 0.210 |
Why?
|
Oncogene Proteins, Fusion | 2 | 2018 | 755 | 0.210 |
Why?
|
Preoperative Care | 2 | 2019 | 1529 | 0.210 |
Why?
|
Bone Marrow | 2 | 2020 | 2360 | 0.200 |
Why?
|
Peritoneal Cavity | 1 | 2021 | 56 | 0.200 |
Why?
|
Benchmarking | 1 | 2024 | 272 | 0.200 |
Why?
|
Sarcoma, Alveolar Soft Part | 1 | 2022 | 75 | 0.200 |
Why?
|
Appendix | 1 | 2021 | 41 | 0.200 |
Why?
|
Motor Activity | 2 | 2004 | 693 | 0.190 |
Why?
|
Paraproteins | 1 | 2021 | 39 | 0.190 |
Why?
|
Whole Body Imaging | 4 | 2024 | 114 | 0.190 |
Why?
|
Foot Injuries | 1 | 2020 | 13 | 0.190 |
Why?
|
Radiation Injuries | 2 | 2020 | 1412 | 0.180 |
Why?
|
Nephrogenic Fibrosing Dermopathy | 1 | 2019 | 10 | 0.180 |
Why?
|
Adolescent | 13 | 2024 | 31257 | 0.180 |
Why?
|
Anterior Cruciate Ligament Injuries | 1 | 2020 | 52 | 0.180 |
Why?
|
Histiocytoma, Malignant Fibrous | 1 | 2020 | 51 | 0.180 |
Why?
|
Activities of Daily Living | 1 | 2023 | 560 | 0.180 |
Why?
|
Neoplasms | 3 | 2024 | 15204 | 0.180 |
Why?
|
Artifacts | 2 | 2023 | 532 | 0.180 |
Why?
|
Spinal Cord Diseases | 1 | 2020 | 90 | 0.180 |
Why?
|
Hemangiosarcoma | 1 | 2022 | 235 | 0.170 |
Why?
|
Bone Resorption | 2 | 2019 | 139 | 0.170 |
Why?
|
Digestive System Neoplasms | 1 | 2020 | 82 | 0.170 |
Why?
|
Reproducibility of Results | 2 | 2023 | 6036 | 0.170 |
Why?
|
Sclerosis | 1 | 2019 | 84 | 0.170 |
Why?
|
Leukemia, Plasma Cell | 1 | 2019 | 42 | 0.170 |
Why?
|
Pain Measurement | 4 | 2018 | 983 | 0.170 |
Why?
|
Colitis | 1 | 2022 | 340 | 0.170 |
Why?
|
Decompression, Surgical | 2 | 2016 | 144 | 0.170 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2024 | 1651 | 0.170 |
Why?
|
Deltoid Muscle | 1 | 2018 | 4 | 0.170 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 7 | 2022 | 15874 | 0.170 |
Why?
|
Knee | 1 | 2018 | 33 | 0.160 |
Why?
|
Stereotaxic Techniques | 2 | 2016 | 172 | 0.160 |
Why?
|
Bone Transplantation | 1 | 2019 | 134 | 0.160 |
Why?
|
Search Engine | 1 | 2018 | 22 | 0.160 |
Why?
|
Osteogenesis | 2 | 2019 | 272 | 0.160 |
Why?
|
Musculoskeletal System | 1 | 2018 | 35 | 0.160 |
Why?
|
Thrombophlebitis | 1 | 2018 | 31 | 0.160 |
Why?
|
Hip Fractures | 1 | 2019 | 76 | 0.160 |
Why?
|
Shoulder Injuries | 1 | 2018 | 37 | 0.160 |
Why?
|
Probability | 1 | 2020 | 868 | 0.160 |
Why?
|
Shoulder Pain | 1 | 2018 | 35 | 0.160 |
Why?
|
Artificial Intelligence | 1 | 2022 | 389 | 0.150 |
Why?
|
Postoperative Care | 2 | 2019 | 738 | 0.150 |
Why?
|
Pelvic Bones | 1 | 2018 | 95 | 0.150 |
Why?
|
Spondylarthropathies | 1 | 2017 | 4 | 0.150 |
Why?
|
Heart Neoplasms | 1 | 2020 | 215 | 0.150 |
Why?
|
Sacroiliitis | 1 | 2017 | 4 | 0.150 |
Why?
|
United States | 11 | 2020 | 15561 | 0.150 |
Why?
|
Asphyxia | 1 | 2017 | 21 | 0.150 |
Why?
|
Ultrasonography | 2 | 2021 | 1866 | 0.150 |
Why?
|
Leiomyoma | 1 | 2018 | 146 | 0.150 |
Why?
|
Adipocytes | 1 | 2019 | 304 | 0.150 |
Why?
|
False Positive Reactions | 2 | 2015 | 351 | 0.150 |
Why?
|
Giant Cell Tumor of Bone | 1 | 2017 | 52 | 0.150 |
Why?
|
Back Pain | 1 | 2017 | 62 | 0.150 |
Why?
|
Pyrrolidinones | 1 | 2017 | 61 | 0.150 |
Why?
|
Cellular Reprogramming | 1 | 2019 | 194 | 0.150 |
Why?
|
Proto-Oncogene Proteins c-met | 2 | 2017 | 419 | 0.150 |
Why?
|
Peripheral Nervous System Neoplasms | 1 | 2017 | 72 | 0.140 |
Why?
|
Anthracyclines | 3 | 2024 | 331 | 0.140 |
Why?
|
Fibula | 1 | 2018 | 146 | 0.140 |
Why?
|
Simulation Training | 1 | 2019 | 149 | 0.140 |
Why?
|
Denosumab | 1 | 2017 | 68 | 0.140 |
Why?
|
Neuronavigation | 1 | 2017 | 47 | 0.140 |
Why?
|
Thymidine Phosphorylase | 1 | 2016 | 23 | 0.140 |
Why?
|
Follow-Up Studies | 11 | 2021 | 14904 | 0.140 |
Why?
|
Disease Progression | 3 | 2021 | 6695 | 0.140 |
Why?
|
Neuroectodermal Tumors | 1 | 2016 | 35 | 0.140 |
Why?
|
Arthritis, Infectious | 1 | 2017 | 71 | 0.140 |
Why?
|
Databases, Factual | 1 | 2024 | 2234 | 0.140 |
Why?
|
ROC Curve | 1 | 2020 | 1180 | 0.140 |
Why?
|
Stomach Neoplasms | 2 | 2019 | 2282 | 0.140 |
Why?
|
Body Composition | 1 | 2019 | 596 | 0.140 |
Why?
|
Pneumonia | 1 | 2022 | 754 | 0.140 |
Why?
|
DNA Copy Number Variations | 1 | 2023 | 1516 | 0.140 |
Why?
|
Teaching | 1 | 2018 | 245 | 0.140 |
Why?
|
Soft Tissue Infections | 1 | 2017 | 102 | 0.140 |
Why?
|
Joint Instability | 1 | 2016 | 88 | 0.130 |
Why?
|
Image Enhancement | 1 | 2019 | 562 | 0.130 |
Why?
|
Cyst Fluid | 1 | 2015 | 21 | 0.130 |
Why?
|
Incidence | 5 | 2019 | 5709 | 0.130 |
Why?
|
Knee Joint | 1 | 2016 | 172 | 0.130 |
Why?
|
Neoplasms, Second Primary | 1 | 2024 | 1351 | 0.130 |
Why?
|
Transcriptome | 2 | 2021 | 1860 | 0.130 |
Why?
|
Knee Injuries | 1 | 2015 | 64 | 0.130 |
Why?
|
Musculoskeletal Diseases | 1 | 2016 | 86 | 0.130 |
Why?
|
Peripheral Nerve Injuries | 1 | 2015 | 60 | 0.130 |
Why?
|
Multiple Trauma | 1 | 2015 | 64 | 0.130 |
Why?
|
Gastric Mucosa | 1 | 2019 | 613 | 0.130 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 992 | 0.130 |
Why?
|
Waldenstrom Macroglobulinemia | 1 | 2018 | 273 | 0.130 |
Why?
|
Intestinal Neoplasms | 1 | 2016 | 189 | 0.130 |
Why?
|
Radiotherapy Dosage | 6 | 2019 | 3847 | 0.120 |
Why?
|
Gastrointestinal Stromal Tumors | 1 | 2017 | 297 | 0.120 |
Why?
|
Adipose Tissue | 1 | 2019 | 766 | 0.120 |
Why?
|
Osteomyelitis | 1 | 2017 | 237 | 0.120 |
Why?
|
Thoracic Wall | 1 | 2016 | 184 | 0.120 |
Why?
|
Aftercare | 1 | 2016 | 261 | 0.120 |
Why?
|
Prospective Studies | 6 | 2022 | 12914 | 0.120 |
Why?
|
Lung | 1 | 2005 | 3157 | 0.120 |
Why?
|
Radiation Tolerance | 1 | 2017 | 629 | 0.120 |
Why?
|
Phenylurea Compounds | 1 | 2017 | 581 | 0.120 |
Why?
|
Carcinoma, Renal Cell | 2 | 2016 | 2327 | 0.120 |
Why?
|
Cysts | 1 | 2015 | 197 | 0.120 |
Why?
|
Quinolines | 1 | 2017 | 384 | 0.120 |
Why?
|
Cryosurgery | 1 | 2015 | 168 | 0.120 |
Why?
|
Femoral Neoplasms | 1 | 2014 | 64 | 0.120 |
Why?
|
Hip Dislocation | 1 | 2014 | 27 | 0.120 |
Why?
|
Cancer Pain | 1 | 2018 | 312 | 0.120 |
Why?
|
Pyridines | 2 | 2017 | 1245 | 0.110 |
Why?
|
Papilloma | 1 | 2013 | 75 | 0.110 |
Why?
|
Thoracic Neoplasms | 1 | 2016 | 337 | 0.110 |
Why?
|
Tumor Microenvironment | 2 | 2022 | 2868 | 0.110 |
Why?
|
Dexamethasone | 4 | 2019 | 1450 | 0.110 |
Why?
|
Antineoplastic Agents, Immunological | 1 | 2022 | 1251 | 0.110 |
Why?
|
Pain Management | 1 | 2018 | 670 | 0.110 |
Why?
|
Spinal Cord Injuries | 1 | 2016 | 374 | 0.110 |
Why?
|
Child | 7 | 2023 | 29135 | 0.110 |
Why?
|
Neurofibromatosis 1 | 1 | 2014 | 144 | 0.110 |
Why?
|
Hamartoma | 1 | 2013 | 115 | 0.110 |
Why?
|
Survival Rate | 7 | 2020 | 12236 | 0.100 |
Why?
|
Coronavirus Infections | 1 | 2020 | 651 | 0.100 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 715 | 0.100 |
Why?
|
Hemangioma | 1 | 2013 | 154 | 0.100 |
Why?
|
Extremities | 1 | 2013 | 303 | 0.100 |
Why?
|
Nervous System Diseases | 1 | 2016 | 499 | 0.100 |
Why?
|
Education, Medical, Graduate | 1 | 2017 | 680 | 0.100 |
Why?
|
Kaplan-Meier Estimate | 5 | 2020 | 6219 | 0.100 |
Why?
|
Spermatic Cord Torsion | 1 | 2011 | 9 | 0.100 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2020 | 5339 | 0.100 |
Why?
|
Carcinoid Tumor | 1 | 2013 | 280 | 0.100 |
Why?
|
Cholecystitis, Acute | 1 | 2011 | 17 | 0.100 |
Why?
|
Carcinoma, Small Cell | 1 | 2013 | 408 | 0.090 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2018 | 1215 | 0.090 |
Why?
|
Surgical Flaps | 1 | 2016 | 927 | 0.090 |
Why?
|
Early Detection of Cancer | 1 | 2018 | 1266 | 0.090 |
Why?
|
Lung Neoplasms | 4 | 2020 | 11573 | 0.090 |
Why?
|
Disease-Free Survival | 5 | 2021 | 10009 | 0.090 |
Why?
|
Survival Analysis | 5 | 2019 | 9186 | 0.090 |
Why?
|
Neoplasm Staging | 4 | 2019 | 13672 | 0.090 |
Why?
|
Doxorubicin | 3 | 2023 | 3005 | 0.090 |
Why?
|
Pain, Postoperative | 1 | 2014 | 619 | 0.080 |
Why?
|
Risk Assessment | 3 | 2019 | 6891 | 0.080 |
Why?
|
Radiography | 1 | 2013 | 1912 | 0.080 |
Why?
|
Child, Preschool | 3 | 2018 | 16256 | 0.080 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2011 | 340 | 0.080 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2018 | 1666 | 0.080 |
Why?
|
Registries | 1 | 2015 | 2187 | 0.080 |
Why?
|
Acute Coronary Syndrome | 1 | 2011 | 262 | 0.080 |
Why?
|
Rats, Inbred WKY | 2 | 2004 | 110 | 0.080 |
Why?
|
Hip Joint | 1 | 2007 | 59 | 0.080 |
Why?
|
Rats, Inbred SHR | 2 | 2004 | 113 | 0.080 |
Why?
|
Algorithms | 2 | 2022 | 3891 | 0.070 |
Why?
|
Pulmonary Embolism | 1 | 2011 | 329 | 0.070 |
Why?
|
Medical Oncology | 1 | 2016 | 1425 | 0.070 |
Why?
|
Palliative Care | 1 | 2018 | 2035 | 0.070 |
Why?
|
Bortezomib | 2 | 2019 | 544 | 0.070 |
Why?
|
Rats | 3 | 2004 | 6109 | 0.070 |
Why?
|
Oligopeptides | 2 | 2019 | 430 | 0.070 |
Why?
|
Analysis of Variance | 3 | 2015 | 2311 | 0.070 |
Why?
|
Species Specificity | 2 | 2004 | 775 | 0.070 |
Why?
|
Membrane Potentials | 2 | 2004 | 425 | 0.070 |
Why?
|
Kidney Neoplasms | 2 | 2016 | 3023 | 0.070 |
Why?
|
Osteoblasts | 2 | 2019 | 369 | 0.070 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2018 | 3553 | 0.070 |
Why?
|
Prostatic Neoplasms | 1 | 2022 | 5777 | 0.070 |
Why?
|
Thyroid Neoplasms | 1 | 2016 | 1867 | 0.070 |
Why?
|
Medulla Oblongata | 1 | 2005 | 45 | 0.060 |
Why?
|
Practice Guidelines as Topic | 1 | 2015 | 2421 | 0.060 |
Why?
|
3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 1 | 2004 | 8 | 0.060 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2019 | 666 | 0.060 |
Why?
|
Clinical Trials, Phase I as Topic | 2 | 2019 | 604 | 0.060 |
Why?
|
Photoperiod | 1 | 2004 | 31 | 0.060 |
Why?
|
Potassium Channels, Calcium-Activated | 1 | 2004 | 13 | 0.060 |
Why?
|
Genetic Predisposition to Disease | 1 | 2018 | 5541 | 0.060 |
Why?
|
Feedback | 1 | 2005 | 206 | 0.060 |
Why?
|
Infant | 2 | 2018 | 13299 | 0.060 |
Why?
|
Titanium | 1 | 2023 | 61 | 0.060 |
Why?
|
Ion Channel Gating | 1 | 2004 | 143 | 0.060 |
Why?
|
Ketones | 1 | 2023 | 54 | 0.060 |
Why?
|
Animals | 7 | 2023 | 59534 | 0.060 |
Why?
|
Treatment Failure | 2 | 2017 | 1392 | 0.050 |
Why?
|
Rats, Sprague-Dawley | 2 | 2004 | 2074 | 0.050 |
Why?
|
Computer Simulation | 2 | 2005 | 1532 | 0.050 |
Why?
|
S100 Proteins | 1 | 2023 | 181 | 0.050 |
Why?
|
Remission Induction | 2 | 2019 | 3577 | 0.050 |
Why?
|
Down-Regulation | 2 | 2019 | 2078 | 0.050 |
Why?
|
Femur | 1 | 2023 | 158 | 0.050 |
Why?
|
Potassium | 1 | 2003 | 330 | 0.050 |
Why?
|
Disease Management | 2 | 2020 | 1060 | 0.050 |
Why?
|
Synaptic Transmission | 1 | 2005 | 443 | 0.050 |
Why?
|
Sodium | 1 | 2003 | 353 | 0.050 |
Why?
|
Retinal Ganglion Cells | 1 | 2003 | 146 | 0.050 |
Why?
|
Colorectal Neoplasms | 1 | 2017 | 3583 | 0.050 |
Why?
|
Cyclophosphamide | 2 | 2019 | 3002 | 0.050 |
Why?
|
Dopamine | 1 | 2003 | 312 | 0.050 |
Why?
|
Up-Regulation | 2 | 2019 | 2449 | 0.050 |
Why?
|
Imaging, Three-Dimensional | 2 | 2016 | 927 | 0.050 |
Why?
|
Patient Selection | 2 | 2020 | 2059 | 0.050 |
Why?
|
Biomarkers, Tumor | 1 | 2020 | 10356 | 0.050 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2018 | 6560 | 0.050 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2023 | 725 | 0.050 |
Why?
|
Polyethylene Glycols | 1 | 2023 | 621 | 0.040 |
Why?
|
Recurrence | 2 | 2019 | 4764 | 0.040 |
Why?
|
Logistic Models | 2 | 2019 | 3450 | 0.040 |
Why?
|
Liver Neoplasms | 1 | 2016 | 4561 | 0.040 |
Why?
|
Health Status | 1 | 2023 | 604 | 0.040 |
Why?
|
Behavior, Animal | 1 | 2003 | 711 | 0.040 |
Why?
|
Cross-Sectional Studies | 2 | 2020 | 4330 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2004 | 4943 | 0.040 |
Why?
|
Salivary Glands | 1 | 2019 | 130 | 0.040 |
Why?
|
Multivariate Analysis | 2 | 2017 | 4321 | 0.040 |
Why?
|
Adipokines | 1 | 2019 | 96 | 0.040 |
Why?
|
Immunotherapy | 2 | 2022 | 3345 | 0.040 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2015 | 5436 | 0.040 |
Why?
|
Antineoplastic Agents | 2 | 2021 | 14301 | 0.040 |
Why?
|
beta Catenin | 1 | 2022 | 687 | 0.040 |
Why?
|
Eligibility Determination | 1 | 2018 | 77 | 0.040 |
Why?
|
Sp1 Transcription Factor | 1 | 2019 | 188 | 0.040 |
Why?
|
Polycomb Repressive Complex 2 | 1 | 2019 | 160 | 0.040 |
Why?
|
PPAR gamma | 1 | 2019 | 230 | 0.040 |
Why?
|
Breast Neoplasms | 1 | 2022 | 15708 | 0.040 |
Why?
|
Retreatment | 1 | 2019 | 452 | 0.040 |
Why?
|
Neurosurgical Procedures | 1 | 2023 | 610 | 0.040 |
Why?
|
Asymptomatic Diseases | 1 | 2018 | 100 | 0.040 |
Why?
|
Enhancer of Zeste Homolog 2 Protein | 1 | 2019 | 247 | 0.040 |
Why?
|
Contraindications, Procedure | 1 | 2017 | 9 | 0.040 |
Why?
|
Methylation | 1 | 2019 | 596 | 0.040 |
Why?
|
Curettage | 1 | 2017 | 21 | 0.040 |
Why?
|
Proportional Hazards Models | 2 | 2017 | 5008 | 0.040 |
Why?
|
Risk Factors | 3 | 2023 | 17605 | 0.040 |
Why?
|
Veins | 1 | 2018 | 157 | 0.040 |
Why?
|
Magnetic Resonance Angiography | 1 | 2018 | 216 | 0.040 |
Why?
|
Glycolysis | 1 | 2020 | 523 | 0.040 |
Why?
|
Chemoradiotherapy, Adjuvant | 1 | 2020 | 565 | 0.040 |
Why?
|
Core Binding Factor Alpha 1 Subunit | 1 | 2016 | 30 | 0.040 |
Why?
|
Sp7 Transcription Factor | 1 | 2016 | 27 | 0.040 |
Why?
|
Age Factors | 2 | 2017 | 5386 | 0.040 |
Why?
|
Spinal Cord | 1 | 2020 | 693 | 0.040 |
Why?
|
Receptors, CXCR4 | 1 | 2018 | 269 | 0.040 |
Why?
|
Tibia | 1 | 2017 | 131 | 0.030 |
Why?
|
Interferon Regulatory Factors | 1 | 2016 | 75 | 0.030 |
Why?
|
Response Evaluation Criteria in Solid Tumors | 1 | 2016 | 160 | 0.030 |
Why?
|
Osteolysis | 1 | 2016 | 80 | 0.030 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2019 | 867 | 0.030 |
Why?
|
Prednisone | 1 | 2019 | 983 | 0.030 |
Why?
|
Time Factors | 3 | 2020 | 12967 | 0.030 |
Why?
|
Intraoperative Care | 1 | 2017 | 259 | 0.030 |
Why?
|
Karnofsky Performance Status | 1 | 2016 | 175 | 0.030 |
Why?
|
Fluoroscopy | 1 | 2017 | 232 | 0.030 |
Why?
|
RANK Ligand | 1 | 2016 | 119 | 0.030 |
Why?
|
Causality | 1 | 2016 | 178 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2020 | 1032 | 0.030 |
Why?
|
Osteoclasts | 1 | 2016 | 164 | 0.030 |
Why?
|
Maximum Tolerated Dose | 1 | 2018 | 1291 | 0.030 |
Why?
|
Exercise | 1 | 2023 | 1186 | 0.030 |
Why?
|
Cytoreduction Surgical Procedures | 1 | 2019 | 475 | 0.030 |
Why?
|
Anesthesia, General | 1 | 2017 | 239 | 0.030 |
Why?
|
Patient Positioning | 1 | 2017 | 195 | 0.030 |
Why?
|
Injury Severity Score | 1 | 2015 | 237 | 0.030 |
Why?
|
Heterozygote | 1 | 2018 | 1018 | 0.030 |
Why?
|
Fatal Outcome | 1 | 2017 | 828 | 0.030 |
Why?
|
Betacoronavirus | 1 | 2020 | 527 | 0.030 |
Why?
|
Indazoles | 1 | 2016 | 299 | 0.030 |
Why?
|
Vincristine | 1 | 2019 | 1511 | 0.030 |
Why?
|
Radiotherapy, Image-Guided | 1 | 2017 | 306 | 0.030 |
Why?
|
Ultrasonography, Doppler | 1 | 2015 | 232 | 0.030 |
Why?
|
Precision Medicine | 1 | 2022 | 1158 | 0.030 |
Why?
|
Radiation Protection | 1 | 2015 | 205 | 0.030 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2019 | 5188 | 0.030 |
Why?
|
CpG Islands | 1 | 2016 | 631 | 0.030 |
Why?
|
Transplantation, Autologous | 1 | 2018 | 1922 | 0.030 |
Why?
|
DNA (Cytosine-5-)-Methyltransferases | 1 | 2016 | 306 | 0.030 |
Why?
|
Image-Guided Biopsy | 1 | 2016 | 327 | 0.030 |
Why?
|
Stem Cell Transplantation | 1 | 2021 | 1361 | 0.030 |
Why?
|
Neoplasm, Residual | 1 | 2020 | 1668 | 0.030 |
Why?
|
Rituximab | 1 | 2019 | 1535 | 0.030 |
Why?
|
Students, Medical | 1 | 2019 | 418 | 0.030 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2022 | 2289 | 0.030 |
Why?
|
Surgery, Computer-Assisted | 1 | 2015 | 255 | 0.030 |
Why?
|
B7-H1 Antigen | 1 | 2020 | 1022 | 0.030 |
Why?
|
Translocation, Genetic | 1 | 2018 | 1247 | 0.030 |
Why?
|
Germ-Line Mutation | 1 | 2018 | 1047 | 0.030 |
Why?
|
Neutropenia | 1 | 2017 | 968 | 0.030 |
Why?
|
Cell Line, Tumor | 2 | 2019 | 14590 | 0.030 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2016 | 661 | 0.030 |
Why?
|
Promoter Regions, Genetic | 1 | 2019 | 3083 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2020 | 3891 | 0.030 |
Why?
|
Quality of Life | 2 | 2016 | 4577 | 0.030 |
Why?
|
Histones | 1 | 2019 | 1467 | 0.030 |
Why?
|
Research Design | 1 | 2019 | 1562 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2017 | 2300 | 0.020 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2022 | 3262 | 0.020 |
Why?
|
Radiation Dosage | 1 | 2015 | 1016 | 0.020 |
Why?
|
Pandemics | 1 | 2020 | 1566 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2017 | 3478 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2015 | 786 | 0.020 |
Why?
|
Mutation | 2 | 2022 | 15194 | 0.020 |
Why?
|
Fatigue | 1 | 2017 | 1239 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2016 | 1949 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2014 | 637 | 0.020 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2016 | 2233 | 0.020 |
Why?
|
Mice | 2 | 2023 | 34438 | 0.020 |
Why?
|
Cardiac Surgical Procedures | 1 | 2020 | 1234 | 0.020 |
Why?
|
Acute Disease | 1 | 2015 | 2424 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2016 | 1536 | 0.020 |
Why?
|
Radiotherapy, Conformal | 1 | 2015 | 902 | 0.020 |
Why?
|
Pregnancy | 1 | 2022 | 7547 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2022 | 4382 | 0.020 |
Why?
|
Comorbidity | 1 | 2016 | 2394 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2021 | 5157 | 0.020 |
Why?
|
Practice Patterns, Physicians' | 1 | 2017 | 1303 | 0.020 |
Why?
|
Pain | 1 | 2017 | 1675 | 0.020 |
Why?
|
Cell Differentiation | 1 | 2019 | 4051 | 0.020 |
Why?
|
Pyrazoles | 1 | 2016 | 1478 | 0.020 |
Why?
|
Sulfonamides | 1 | 2016 | 1826 | 0.020 |
Why?
|
Hypertension | 1 | 2017 | 1515 | 0.020 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2017 | 2373 | 0.020 |
Why?
|
Biomarkers | 1 | 2018 | 5049 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2020 | 4980 | 0.020 |
Why?
|
Anti-Bacterial Agents | 1 | 2019 | 2995 | 0.020 |
Why?
|
DNA Methylation | 1 | 2016 | 2671 | 0.020 |
Why?
|
Disease Models, Animal | 1 | 2019 | 7226 | 0.020 |
Why?
|
Surveys and Questionnaires | 1 | 2018 | 5714 | 0.020 |
Why?
|
Infant, Newborn | 1 | 2018 | 8220 | 0.020 |
Why?
|
Analgesics, Opioid | 1 | 2014 | 1372 | 0.020 |
Why?
|
Brain | 1 | 2018 | 4113 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2015 | 5121 | 0.020 |
Why?
|
Pyrimidines | 1 | 2016 | 3536 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2015 | 8883 | 0.010 |
Why?
|
Sodium-Potassium-Exchanging ATPase | 1 | 2003 | 132 | 0.010 |
Why?
|
Random Allocation | 1 | 2003 | 705 | 0.010 |
Why?
|
Signal Transduction | 1 | 2019 | 11978 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2003 | 5606 | 0.010 |
Why?
|
Neurons | 1 | 2003 | 2289 | 0.010 |
Why?
|